Compare Keysight Technologies Inc (KEYS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Moderna, Inc. — how do they compare? Keysight Technologies Inc trades at $382.61 (market cap $63.79B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is more actively traded (37,373,437 versus 1,435,384). Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Moderna, Inc. for 59 Days on average.
| KEYS | MRNA | |
|---|---|---|
Market Cap | $63.79B | $78.65B |
Volume | 1,435,384 | 37,373,437 |
Sector | Technology | Health |
52-Week High | $387.90 | $225.00 |
52-Week Low | $159.49 | $22.36 |
Typical Hold Time | 56 Days | 59 Days |
Enterprise Value | $63.93B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KEYS trades at $374.66, down 1.79% on the day, with a bullish technical signal and strong analyst support. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $3.07 exceeding the $2.48 forecast. The company is capitalizing on AI infrastructure and 6G development, as highlighted by a 56% surge in Q3 orders. Valuation ratios are elevated, with a P/E of 50.7 and P/S of 9.85, reflecting high growth expectations.
The outlook is positive, driven by robust AI and 6G demand, but risks include supply constraints and rich valuations. The consensus price target of $416.63 implies significant upside, supported by 13 buy ratings. However, execution risks and market volatility could pressure the stock if growth momentum slows.
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
